Group 1: Fund Performance - Madison Mid Cap Fund (Class Y) returned 5.2% in Q2 2025, underperforming the Russell Midcap Index which increased by 8.5% [1] - The fund's top five holdings were highlighted, indicating its best investment picks for 2025 [1] Group 2: Medpace Holdings, Inc. Overview - Medpace Holdings, Inc. (NASDAQ:MEDP) is a clinical research-based drug and medical device development services provider [2] - The stock of Medpace Holdings, Inc. had a one-month return of 8.26% and a 52-week gain of 37.25%, closing at $501.94 per share with a market capitalization of $14.101 billion on September 18, 2025 [2] Group 3: Investment Insights on Medpace Holdings, Inc. - Madison Mid Cap Fund added Medpace Holdings, Inc. as a new investment in Q2 2025, emphasizing its focus on providing clinical trial services to small biotech companies [3] - The company, led by founder Dr. August Troendle, has a differentiated expertise in oncology and metabolic disorders, with only a ~5% share of the addressable market, indicating significant growth potential [3] - Medpace Holdings, Inc. reported revenue of $603.3 million in Q2 2025, reflecting a year-over-year increase of 14.2% [4]